| Name | Title | Contact Details |
|---|---|---|
Michael Mayes |
Executive Director, Anti-Bribery and Anti-Corruption, Third Party and Distributor Compliance Lead | Profile |
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Harkness Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acadia Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders. Their focus is on developing treatments for dementia-related psychosis, negative symptoms of schizophrenia, and Rett ...
Kalypsys is a clinical stage pharmaceutical company that is advancing the way drugs are discovered and developed. We seamlessly integrate our capabilities in drug discovery, medicinal chemistry and translational medicine with proprietary automated
Chemrx is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.